martes, 23 de junio de 2015

19 REFERENCIAS BIBLIOGRÁFICAS SISTEMA NERVIOSO


  1. Adami, H., Hsing, A. W., McLaughlin, J. K., Trichopoulos, D., Hacker, D., Ekbom, A., & Persson, I. (1992). Alcoholism and liver cirrhosis in the etiology of primary liver cancer. International Journal of Cancer, 51(6), 898–902.
  2. Akhgari, M., Etemadi-Aleagha, A., & Jokar, F. (2016). Street Level Heroin, an Overview on Its Components and Adulterants.
  3. Albert, M. R. (2000). Nineteenth-century patent medicines for the skin and hair. Journal of the American Academy of Dermatology, 43(3), 519–526.
  4. Allan, R. B. (1997). Alcoholism, drug abuse and lawyers: Are we ready to address the denial. Creighton L. Rev., 31, 265.
  5. ALLIS, E. P. (1923). THE CRANIAL ANATOMY OF CHLAMYDO‐SELACHUS ANGUINEUS. Acta Zoologica, 4(2‐3), 123–221.
  6. Allmon, W. D. (2011). Why don’t people think evolution is true? Implications for teaching, in and out of the classroom. Evolution: Education and Outreach, 4(4), 648–665.
  7. Ansel, H. C., Popovich, N. G., & Allen, L. V. (1995). Pharmaceutical dosage forms and drug delivery systems. Lippincott Williams & Wilkins.
  8. Argyropoulos, S. V, & Nutt, D. J. (2013). Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression? Journal of Psychopharmacology, 27(10), 869–877.
  9. Arias Dioses, L. P. (2014). Manejo odontológico de lesiones orales en pacientes con adicciones: revisión bibliográfica. Universidad de Guayaquil. Facultad Piloto de Odontología.
  10. Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychological Review, 111(1), 33.
  11. Bear, M. F., Connors, B. W., & Paradiso, M. A. (2006). Neuroscience: Exploring the Brain (3rd ed.). Lippincott Williams and Wilkins.
  12. Bear, M. F., Connors, B. W., & Paradiso, M. A. (2007). Neuroscience (Vol. 2). Lippincott Williams & Wilkins.
  13. Belk, C., & Maier, V. B. (2013). Biology Science for Life with physiology. (Pearson, Ed.) (4th ed.).
  14. Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado-Devincci, A., & Rodd, Z. A. (2017). Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology.
  15. Benowitz, N. L. (2008). Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical Pharmacology & Therapeutics, 83(4).
  16. Bhullar, B.-A. S., Hanson, M., Fabbri, M., Pritchard, A., Bever, G. S., & Hoffman, E. (2016). How to make a bird skull: Major transitions in the evolution of the avian cranium, paedomorphosis, and the beak as a surrogate hand. Integrative and Comparative Biology, icw069.
  17. Blumenfeld, H. (2011). Neuroanatomy Through Clinical Cases (2nd ed.). Sinauer Associates, Inc.
  18. Boerner, U., Abbott, S., & Roe, R. L. (1975). The metabolism of morphine and heroin in man. Drug Metabolism Reviews, 4(1), 39–73.
  19. Bonomo, Y., & Proimos, J. (2005). 8 Substance misuse: alcohol, tobacco, inhalants, and other drugs. ABC of Adolescence, 98, 26.
  20. Bourgois, P., & Schonberg, J. (2007). Intimate apartheid ethnic dimensions of habitus among homeless heroin injectors. Ethnography, 8(1), 7–31.
  21. Bradberry, C. W. (2002). Book Review: Dynamics of Extracellular Dopamine in the Acute and Chronic Actions of Cocaine. The Neuroscientist, 8(4), 315–322.
  22. Brook, T., & Wakabayashi, B. T. (2016). The Opium Wars. Shooting Up: A Short History of Drugs and War, 58.
  23. Brusca, R., Brusca, G. J., & Haver, N. J. (2003). Invertebrates (2nd ed.). Sinauer Associates.
  24. Burish, M. J., Kueh, H. Y., & Wang, S.-H. (2004). Brain architecture and social complexity in modern and ancient birds. Brain, Behavior and Evolution, 63(2), 107–124.
  25. Butler, A. B., & Hodos, W. (2005). Comparative vertebrate neuroanatomy: evolution and adaptation. John Wiley & Sons.
  26. Buvinic, M., Morrison, A., & Orlando, M. B. (2005). Violencia, crimen y desarrollo social en América Latina y el Caribe. Papeles de Población, 11(43), 167–214.
  27. Cagniard, B., Sotnikova, T. D., Gainetdinov, R. R., & Zhuang, X. (2014). The dopamine transporter expression level differentially affects responses to cocaine and amphetamine. Journal of Neurogenetics, 28(1-2), 112–121.
  28. Callaghan, R. C., Allebeck, P., & Sidorchuk, A. (2013). Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes & Control, 24(10), 1811–1820.
  29. Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016). Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction. European Journal of Pharmacology, 780, 129–135.
  30. Carmona, J. S. S., & Novoa, J. R. U. (2012). Composición química de muestras de bazuco incautado en Colombia primer semestre de 2010. Revista de Salúd Publica= Journal of Public Health, 14(6), 1010.
  31. Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014). Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12–41.
  32. Cecinato, A., Balducci, C., & Nervegna, G. (2009). Occurrence of cocaine in the air of the World’s cities: An emerging problem? A new tool to investigate the social incidence of drugs? Science of the Total Environment, 407(5), 1683–1690.
  33. Celofiga, A., Koprivsek, J., & Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of Dual Diagnosis, 10(3), 168–173.
  34. Cervantes, M. L. (2003). Características neuropsicológicas en adultos policonsumidores de alcohol, marihuana, bazuco y cocaína entre las edades de 20-50 años de la ciudad de Barranquilla. J. Acosta, M. Cervantes, P. Puentes, M. Núñez, G. Jiménez, M. Sánchez, A. Berrío, M. Zapata (Comps.), Grupo Neurociencias Del Caribe-Trayectoria Investigativa, 2005, 35–85.
  35. Chaisson, R. E., Bacchetti, P., Osmond, D., Brodie, B., Sande, M. A., & Moss, A. R. (1989). Cocaine use and HIV infection in intravenous drug users in San Francisco. Jama, 261(4), 561–565.
  36. Chapman, L. J., Chapman, J. P., & Raulin, M. L. (1976). Scales for physical and social anhedonia. Journal of Abnormal Psychology, 85(4), 374.
  37. Chapman, L. J., Edell, W. S., & Chapman, J. P. (1980). Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophrenia Bulletin, 6(4), 639.
  38. Christen, A. G., & Christen, J. A. (2000). Sozodont powder dentifrice and Mrs. Winslow’s Soothing Syrup: dental nostrums. Journal of the History of Dentistry, 48(3), 99–105.
  39. Chuang, S.-C., La Vecchia, C., & Boffetta, P. (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Letters, 286(1), 9–14.
  40. Cleveland, H. J., Keen, S., Larson, A., I´Anson, H., & Roberts, R. (2013). Integrated Principles of Zoology (16th ed.). McGraw-Hill Education.
  41. Concha, A. (2002). Impacto social y económico de la violencia en las Américas. Biomédica, 22(Sup2), 347–361.
  42. Covey, D. P., Bunner, K. D., Schuweiler, D. R., Cheer, J. F., & Garris, P. A. (2016). Amphetamine elevates nucleus accumbens dopamine via an action potential‐dependent mechanism that is modulated by endocannabinoids. European Journal of Neuroscience, 43(12), 1661–1673.
  43. Creese, I. (1983). Stimulants, neurochemical, behavioral, and clinical perspectives (Vol. 4). Raven Press (ID).
  44. Dai, J., Mukamal, K. J., Krasnow, R. E., Swan, G. E., & Reed, T. (2015). Higher usual alcohol consumption was associated with a lower 41-y mortality risk from coronary artery disease in men independent of genetic and common environmental factors: the prospective NHLBI Twin Study. The American Journal of Clinical Nutrition, 102(1), 31–39.
  45. Daniel, J. F. (1922). The elasmobranch fishes. University of California Press.
  46. Davies, J. A., & Graham, J. D. P. (1980). The mechanism of action of Δ 9-tetrahydrocannabinol on body temperature in mice. Psychopharmacology, 69(3), 299–305.
  47. Day, C. P., & Bassendine, M. F. (1992). Genetic predisposition to alcoholic liver disease. Gut, 33(11), 1444–1447.
  48. de Alwis, N. M. W., & Day, C. P. (2007). Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. In Seminars in liver disease (Vol. 27, pp. 44–54). Copyright© 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
  49. Deugnier, Y. M., Guyader, D., Crantock, L., Lopez, J.-M., Turlin, B., Yaouanq, J., … Halliday, J. W. (1993). Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. GASTROENTEROLOGY-BALTIMORE THEN PHILADELPHIA-, 104, 228.
  50. Di Marzo, V., & Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 8(5), 585–589.
  51. Diaz, J. H. Q., & Fernandez, M. C. O. (2013). Consumo de marihuana en estudiantes de una universidad colombiana. Revista de Salúd Publica= Journal of Public Health, 15(1), 32.
  52. Donoghue, P. C. J., & Keating, J. N. (2014). Early vertebrate evolution. Palaeontology, 57(5), 879–893.
  53. Duane, E. H. (2014). Neuroanatomy in Clinical Context: An Atlas of Structures, Sections, Systems, and Syndromes (9th ed.). LWW.
  54. Elman, I., Borsook, D., & Volkow, N. D. (2013). Pain and suicidality: insights from reward and addiction neuroscience. Progress in Neurobiology, 109, 1–27.
  55. ELTIEMPO.COM. (2015, August 18). Alarmante radiografía de consumo de drogas en colegios distritales. El Tiempo. Bogotá. Retrieved from http://www.eltiempo.com/bogota/estudio-sobre-consumo-de-drogas-en-colegios-de-bogota/16249537
  56. Falk, D., Redmond, J. C., Guyer, J., Conroy, C., Recheis, W., Weber, G. W., & Seidler, H. (2000). Early hominid brain evolution: a new look at old endocasts. Journal of Human Evolution, 38(5), 695–717.
  57. Ferré, S., & O’Brien, M. C. (2011). Alcohol and caffeine: the perfect storm. Journal of Caffeine Research, 1(3), 153–162.
  58. Finch, L. (1999). Soothing syrups and teething powders: Regulating proprietary drugs in Australia, 1860–1910. Medical History, 43(01), 74–94.
  59. Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007). New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol., 47, 681–698.
  60. Foxcroft, L. (2016). The Making of Addiction: The’Use and Abuse'of Opium in Nineteenth-Century Britain. Routledge.
  61. Freeman, D., Dunn, G., Murray, R. M., Evans, N., Lister, R., Antley, A., … Williams, J. (2014). How cannabis causes paranoia: using the intravenous administration of∆ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia Bulletin, sbu098.
  62. Freyberg, Z., Sonders, M. S., Aguilar, J. I., Hiranita, T., Karam, C. S., Flores, J., … Chen, A. (2016). Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 7.
  63. Garrick, J. A. F. (1960). Studies on New Zealand Elasmobranchii. Part XII. The species of Squalus from New Zealand and Australia; and a general account and key to the New Zealand Squaloidea. In Transactions of the Royal Society of New Zealand (Vol. 88, pp. 519–557).
  64. George, A. J. (2000). Central nervous system stimulants. Best Practice & Research Clinical Endocrinology & Metabolism, 14(1), 79–88.
  65. Goodenough, J., & McGuire, B. (2012). Biology of Humans, Concepts, Applications and Issues (4th ed.). San Francisco: Pearson, Benjamin Cummings.
  66. Granger, C. D., & Simon, T. H. (1992, September 22). Misuse-resistive transdermal opioid dosage form. Google Patents.
  67. Grenald, S. A., Largent-Milnes, T. M., & Vanderah, T. W. (2014). Animal models for opioid addiction drug discovery. Expert Opinion on Drug Discovery, 9(11), 1345–1354.
  68. Grinspoon, L., & Bakalar, J. B. (1981). Coca and cocaine as medicines: an historical review. Journal of Ethnopharmacology, 3(2-3), 149–159.
  69. Hall, B. K., & Gillis, J. A. (2013). Incremental evolution of the neural crest, neural crest cells and neural crest‐derived skeletal tissues. Journal of Anatomy, 222(1), 19–31.
  70. Harner, M. J. (1973). Hallucinogens and shamanism. Oxford U. Press.
  71. Hartmann, T., & Ober, D. (2000). Biosynthesis and metabolism of pyrrolizidine alkaloids in plants and specialized insect herbivores. In Biosynthesis (pp. 207–243). Springer.
  72. Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., … Smith, S. M. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235–1242.
  73. Herman, A. I., DeVito, E. E., Jensen, K. P., & Sofuoglu, M. (2014). Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics, 15(2), 221–234.
  74. Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 108(3), 534–544.
  75. Hillard, C. J. (2015). Endocannabinoids and the endocrine system in health and disease. In Endocannabinoids (pp. 317–339). Springer.
  76. Hoefnagels, M. (2015). Biology: concepts and investigations (3rd ed.). McGraw-Hill New York.
  77. Hopenhayn, M. (1997). La grieta de las drogas: desintegración social y políticas públicas en América Latina. Cepal.
  78. Huang, Y.-H. J., Zhang, Z.-F., Tashkin, D. P., Feng, B., Straif, K., & Hashibe, M. (2015). An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiology and Prevention Biomarkers, 24(1), 15–31.
  79. Hurlburt, G. R., Ridgely, R. C., & Witmer, L. M. (2013). Relative size of brain and cerebrum in tyrannosaurid dinosaurs: an analysis using brain-endocast quantitative relationships in extant alligators. Tyrannosaurid Paleobiology, 1–21.
  80. Jay, M. (2015). Chapter Three-Miracle or Menace?: The Arrival of Cocaine 1860–1900. International Review of Neurobiology, 120, 27–39.
  81. Jerison, H. J. (1969). Brain evolution and dinosaur brains. The American Naturalist, 103(934), 575–588.
  82. Jonathan, O. (2006). Escenarios farmacófilos de la cocaína en Manizales:“patraseando” por la “pocaína” a la “cocaína”: del bazuco al ladruco. revista Cultura y Droga.
  83. Joranson, D. E., Ryan, K. M., Gilson, A. M., & Dahl, J. L. (2000). Trends in medical use and abuse of opioid analgesics. Jama, 283(13), 1710–1714.
  84. Justicia. (2016, December 26). Los millonarios hilos que mueven la indigencia en el país. El Tiempo. Bogotá. Retrieved from http://www.eltiempo.com/politica/justicia/cifras-de-habitantes-de-calle-en-colombia/16780702
  85. Jylhä, K. M., Cantal, C., Akrami, N., & Milfont, T. L. (2016). Denial of anthropogenic climate change: Social dominance orientation helps explain the conservative male effect in Brazil and Sweden. Personality and Individual Differences, 98, 184–187.
  86. Kaas, J. H. (2016). of Brain Evolution. The Wiley Handbook of Evolutionary Neuroscience, 38.
  87. Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (2000). Principles of Neural Science (4th ed.). McGraw-Hill Medical.
  88. Kardong, K. V. (2011). Vertebrates, comparative anatomy, function, evolution (6th ed.). McGraw-Hill New York.
  89. Karp, G. C. (2013). Cell and Molecular Biology, Concepts and Experiments (7th ed.). USA: Wiley Online Library.
  90. Kerr, T., Tyndall, M., Li, K., Montaner, J., & Wood, E. (2005). Safer injection facility use and syringe sharing in injection drug users. The Lancet, 366(9482), 316–318.
  91. la Haye, K., Green, H. D., Kennedy, D. P., Pollard, M. S., & Tucker, J. S. (2013). Selection and influence mechanisms associated with marijuana initiation and use in adolescent friendship networks. Journal of Research on Adolescence, 23(3), 474–486.
  92. Larsson, H. C. E., Sereno, P. C., & Wilson, J. A. (2000). Forebrain enlargement among nonavian theropod dinosaurs. Journal of Vertebrate Paleontology, 20(3), 615–618.
  93. Launchbaugh, K. L., Provenza, F. D., & Pfister, J. A. (2001). Herbivore response to anti-quality factors in forages. Journal of Range Management, 431–440.
  94. Levin, D. A. (1976). The chemical defenses of plants to pathogens and herbivores. Annual Review of Ecology and Systematics, 7(1), 121–159.
  95. Lewandowsky, S., Oreskes, N., Risbey, J. S., Newell, B. R., & Smithson, M. (2015). Seepage: Climate change denial and its effect on the scientific community. Global Environmental Change, 33, 1–13.
  96. Li, G.-H., Anderson, C., Jaeger, L., Do, T., Major, E. O., & Nath, A. (2015). Cell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4. AIDS, 29(7), 755–766.
  97. López-Quintero, C., & Neumark, Y. (2012). Membresía a barras bravas y su influencia en el uso de drogas. Revista Peruana de Medicina Experimental Y Salud Pública, 29(1), 21–27.
  98. Maertens, R. M., White, P. A., Rickert, W., Levasseur, G., Douglas, G. R., Bellier, P. V, … Desjardins, S. (2009). The genotoxicity of mainstream and sidestream marijuana and tobacco smoke condensates. Chemical Research in Toxicology, 22(8), 1406–1414.
  99. Marino, L., Uhen, M. D., Pyenson, N. D., & Frohlich, B. (2003). Reconstructing cetacean brain evolution using computed tomography. The Anatomical Record, 272(1), 107–117.
  100. Markowitz, G., & Rosner, D. (2013). Deceit and denial: The deadly politics of industrial pollution. Univ of California Press.
  101. Marselos, M., & Karamanakos, P. (1999). Mutagenicity, developmental toxicity and carcinogenicity of cannabis. Addiction Biology, 4(1), 5–12.
  102. Martin, B. R., & Wiley, J. L. (2003). Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. The Journal of Supportive Oncology, 2(4), 305–314.
  103. MARTÍNEZ, I. P., & AMAR, J. A. (n.d.). DISTORSIONES COGNITIVAS EN LOS GRUPOS DE DROGODEPENDIENTES CON DIAGNÓSTICO DUAL.
  104. Martínez Ruiz, M., & Rubio Valladolid, G. (2002). Manual de drogodependencias para enfermería. Ediciones Díaz de Santos.
  105. Martínez-González, J. M., Vilar López, R., Becoña Iglesias, E., & Verdejo-García, A. (2016). Self-deception as a mechanism for the maintenance of drug addiction. Psicothema, 28(1).
  106. Mason, K. A., Losos, J. B., Singer, S. R., & Raven, P. H. (2014). Biology (7th ed.). McGraw-Hill New York.
  107. Matsumoto, C., Miedema, M. D., Ofman, P., Gaziano, J. M., & Sesso, H. D. (2014). An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 34(3), 159–171.
  108. McBride, W. J., Murphy, J. M., Lumeng, L., & Li, T.-K. (1990). Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats. Alcohol, 7(3), 199–205.
  109. McKim, W. A., & Hancock, S. (2012). Drugs & Behavior. Pearson Higher Ed.
  110. Mei, W., Zhang, J. X., & Xiao, Z. (2010). Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: an uncontrolled trial. Neuroscience, 170(3), 808–815.
  111. Mejía, I. E., & Gómez, A. P. (2005). La inyección de drogas en Bogotá: una amenaza creciente. Adicciones, 17(3), 251–260.
  112. Mendoza, A., Romero, J. F. R., Mendoza, G. A. G., & Posada, I. C. (2015). Significados del consumo de sustancias psicoactivas en indígenas estudiantes de una universidad de Medellín, Colombia. Universitas Psychologica, 14(3).
  113. Mesa, A. F. C., & Bello, S. M. L. (2015). Cannabis sintético: aspectos toxicológicos, usos clínicos y droga de diseño. Revista de La Facultad de Medicina, 63(3), 501.
  114. Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M., & Eisdorfer, C. (2002). The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. Journal of the Neurological Sciences, 202(1), 13–23.
  115. Mithöfer, A., & Boland, W. (2012). Plant defense against herbivores: chemical aspects. Annual Review of Plant Biology, 63, 431–450.
  116. Moore, J. (2006). Introduction to the invertebrates (2nd ed.). Cambridge: Cambridge Univ Press.
  117. Moreira, F. A., & Dalley, J. W. (2015). Dopamine receptor partial agonists and addiction. European Journal of Pharmacology, 752, 112–115.
  118. Morrow, A. L., Montpied, P., Lingford-Hughes, A., & Paul, S. M. (1990). Chronic ethanol and pentobarbital administration in the rat: effects on GABA A receptor function and expression in brain. Alcohol, 7(3), 237–244.
  119. Most, D., Ferguson, L., & Harris, R. A. (2014). Molecular basis of alcoholism. Handbook of Clinical Neurology, 125, 89.
  120. Musshoff, F., Madea, B., Kernbach-Wighton, G., Bicker, W., Kneisel, S., Hutter, M., & Auwärter, V. (2014). Driving under the influence of synthetic cannabinoids (“Spice”): a case series. International Journal of Legal Medicine, 128(1), 59–64.
  121. Naguib, M., & Foss, J. F. (2015). Medical use of marijuana: truth in evidence. LWW.
  122. Neumark, Y. D., Delva, J., & Anthony, J. C. (1998). The epidemiology of adolescent inhalant drug involvement. Archives of Pediatrics & Adolescent Medicine, 152(8), 781–786.
  123. Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181.
  124. Northcutt, R. G. (1984). Evolution of the vertebrate central nervous system: patterns and processes. American Zoologist, 24(3), 701–716.
  125. Northcutt, R. G. (2001). Changing views of brain evolution. Brain Research Bulletin, 55(6), 663–674.
  126. Northcutt, R. G. (2002). Understanding Vertebrate Brain Evolution1. Integrative and Comparative Biology, 42(4), 743–756.
  127. O’shea, R. S., Dasarathy, S., & McCullough, A. J. (2010). Alcoholic liver disease. Hepatology, 51(1), 307–328.
  128. Olin, J. T., Schneider, L. S., Katz, I. R., Meyers, B. S., Alexopoulos, G. S., Breitner, J. C., … Devanand, D. P. (2002). Provisional diagnostic criteria for depression of Alzheimer disease. The American Journal of Geriatric Psychiatry, 10(2), 125–128.
  129. Oreskes, N., & Conway, E. M. (2011). Merchants of doubt: How a handful of scientists obscured the truth on issues from tobacco smoke to global warming. Bloomsbury Publishing USA.
  130. Panksepp, J., Knutson, B., & Burgdorf, J. (2002). The role of brain emotional systems in addictions: a neuro‐evolutionary perspective and new “self‐report”animal model. Addiction, 97(4), 459–469.
  131. Parmar, J. R., Forrest, B. D., & Freeman, R. A. (2016). Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Research in Social and Administrative Pharmacy, 12(4), 638–654.
  132. Pasternak, G. W. (1993). Pharmacological mechanisms of opioid analgesics. Clinical Neuropharmacology, 16(1), 1–18.
  133. Peruaga, A., Rincón, A., & Selin, H. (2002). El consumo de sustancias adictivas en las Américas. Adicciones, 14(2), 227–238.
  134. Pesta, D. H., Angadi, S. S., Burtscher, M., & Roberts, C. K. (2013). The effects of caffeine, nicotine, ethanol, and tetrahydrocannabinol on exercise performance. Nutrition & Metabolism, 10(1), 71.
  135. Picciotto, M. R., & Kenny, P. J. (2013). Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harbor Perspectives in Medicine, 3(1), a012112.
  136. Pickard, H. (2016). Denial in addiction. Mind & Language, 31(3), 277–299.
  137. Portenoy, R. K., & Foley, K. M. (1986). Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain, 25(2), 171–186.
  138. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
  139. Prochaska, J. J., & Benowitz, N. L. (2016). The past, present, and future of nicotine addiction therapy. Annual Review of Medicine, 67, 467–486.
  140. Puig, S., & Gutstein, H. B. (2017). Opioids: keeping the good, eliminating the bad. Nature Medicine.
  141. Radenkova-Saeva, J. (2008). Recreational Drugs and its Impact on Music Literature and Art. Biotechnology & Biotechnological Equipment, 22(2), 656–659.
  142. Rader, D. J., & Hovingh, G. K. (2014). HDL and cardiovascular disease. The Lancet, 384(9943), 618–625.
  143. Ranki, A., Nyberg, M., Ovod, V., Haltia, M., Elovaara, I., Raininko, R., … Krohn, K. (1995). Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. Aids, 9(9), 1001–1008.
  144. Reinecke, M. (1985). Neurotensin: immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Progress in Histochemistry and Cytochemistry, 16(1), III–172.
  145. Rey, J. M., Martin, A., & Krabman, P. (2004). Is the party over? Cannabis and juvenile psychiatric disorder: the past 10 years. Journal of the American Academy of Child & Adolescent Psychiatry, 43(10), 1194–1205.
  146. Rhoades, R. A., & Bell, D. R. (2013). Medical Physiology, Principles for Clinical Medicine (4th ed.). Baltimore: Lippincott Williams & Wilkins.
  147. Richardson, J. L., & Illum, L. (1992). (D) Routes of delivery: Case studies:(8) The vaginal route of peptide and protein drug delivery. Advanced Drug Delivery Reviews, 8(2-3), 341–366.
  148. Rinn, W., Desai, N., Rosenblatt, H., & Gastfriend, D. R. (2002). Addiction denial and cognitive dysfunction: a preliminary investigation. The Journal of Neuropsychiatry and Clinical Neurosciences, 14(1), 52–57.
  149. Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 237, 1219–1224.
  150. Roberto, M., Madamba, S. G., Moore, S. D., Tallent, M. K., & Siggins, G. R. (2003). Ethanol increases GABAergic transmission at both pre-and postsynaptic sites in rat central amygdala neurons. Proceedings of the National Academy of Sciences, 100(4), 2053–2058.
  151. Rogers, S. W. (1999). Allosaurus, crocodiles, and birds: evolutionary clues from spiral computed tomography of an endocast. The Anatomical Record, 257(5), 162–173.
  152. Rojas Valero, M. (2015). Pasta Básica de Cocaína: cuatro décadas de historia, actualidad y desafíos.
  153. Rosslenbroich, B. (2014). Nervous Systems and the Flexibility of Movements. In On the Origin of Autonomy (pp. 131–147). Springer.
  154. Rossum, J. M. van, Schoot, J. B., & Hurkmans, J. A. T. M. (1962). Mechanism of action of cocaine and amphetamine in the brain. Cellular and Molecular Life Sciences, 18(5), 229–231.
  155. Sabogal-Carmona, J. S., & Urrego-Novoa, J. R. (2012). Quantifying the chemical composition of crack-cocaine (bazuco) samples seized in Colombia during the first half of 2010. Revista de Salud Pública, 14(6), 1014–1025.
  156. Sadava, D., Berenbaum, M., & Hillis, D. (2014). Life the Science of Biology (10th ed.). Sinauer & MacMillian.
  157. Sakar, S. (2009). Doubting Darwin?: Creationist designs on evolution. John Wiley & Sons.
  158. Savage, R. J., King, V. L., Clark, C. B., & Cropsey, K. L. (2017). Factors associated with early marijuana initiation in a criminal justice population. Addictive Behaviors, 64, 82–88.
  159. Schneider, M. (2008). Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addiction Biology, 13(2), 253–263.
  160. Schultes, R. E., & Hofmann, A. (1973). The botany and chemistry of hallucinogens. Springfield, Illinois.: Charles C. Thomas 267pp.. Hallucinogens: Fungi.
  161. Schütz, C. G., Chilcoat, H. D., & Anthony, J. C. (1994). The association between sniffing inhalants and injecting drugs. Comprehensive Psychiatry, 35(2), 99–105.
  162. Scoppetta Díaz-Granados, O., Pérez Gómez, A., & Muñoz, V. H. (2013). Sobre la supuesta inocuidad del consumo de marihuana: diferencia entre consumidores y no consumidores en encuestas nacionales en Colombia. Liberabit, 19(1), 55–66.
  163. Scott, E. C. (1997). Antievolution and creationism in the United States. Annual Review of Anthropology, 26(1), 263–289.
  164. Serrano, A. P. (2014, September 1). Adicción al bazuco va más allá de los estratos 1 y 2. El Tiempo. Bogotá. Retrieved from http://www.eltiempo.com/bogota/relatos-de-consumidores-de-bazuco/14462035
  165. Shah, V. P., Maibach, H. I., & Jenner, J. (1993). Topical drug bioavailability, bioequivalence, and penetration. Springer.
  166. Shepherd, G. M. (1994). Neurobiology (3rd ed.). Oxford University Press, USA.
  167. Silverberg, A. B., Shah, S. D., Haymond, M. W., & Cryer, P. E. (1978). Norepinephrine: hormone and neurotransmitter in man. American Journal of Physiology-Endocrinology and Metabolism, 234(3), E252.
  168. Simon, E. J., Dickey, J. L., & Reece, J. B. (2013). Essential biology (Pearson).
  169. Snell, R. S. (2010). Clinical Neuroanatomy (7th ed.). Lippincott Williams & Wilkins.
  170. Solanto, M. V. (2001). Stimulant drugs and ADHD: Basic and clinical neuroscience. Oxford University Press, USA.
  171. Solomon, E. P., Berg, L. R., & Martin, D. W. (2008). Biology 8th edition. Thomsom Brooks/Cole, USA.
  172. Starr, C., Evers, C., & Starr, L. (2013). Biology: Today and Tomorrow With Physiology (4th ed.). Brooks/Cole.
  173. Steinkellner, T., Mus, L., Eisenrauch, B., Constantinescu, A., Leo, D., Konrad, L., … Kong, E. (2014). In vivo amphetamine action is contingent on αCaMKII. Neuropsychopharmacology, 39(11), 2681–2693.
  174. Stern, K. R., Bidlack, J. E., & Jansky, S. H. (2008). Introductory Plant Biology (11th ed.). McGraw-Hill New York.
  175. Subramaniyan, M., & Dani, J. A. (2015). Dopaminergic and cholinergic learning mechanisms in nicotine addiction. Annals of the New York Academy of Sciences, 1349(1), 46–63.
  176. Takeda, S. (2014). Δ9-Tetrahydrocannabinol targeting estrogen receptor signaling: the possible mechanism of action coupled with endocrine disruption. Biological and Pharmaceutical Bulletin, 37(9), 1435–1438.
  177. Tashkin, D. P. (1990). Pulmonary complications of smoked substance abuse. Western Journal of Medicine, 152(5), 525.
  178. Tashkin, D. P. (2001). Airway effects of marijuana, cocaine, and other inhaled illicit agents. Current Opinion in Pulmonary Medicine, 7(2), 43–61.
  179. Tiffany, S. T., Cox, L. S., & Elash, C. A. (2000). Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. Journal of Consulting and Clinical Psychology, 68(2), 233.
  180. Torrens, M., Fonseca, F., Galindo, L., & Farré, M. (2015). Opioid Addiction: Short-and Long-Acting Opioids. Textbook of Addiction Treatment: International Perspectives, 467–500.
  181. Tortajada, R. E., San Miguel, J. P., Domenech, M. G., Cucarella, J. O., & Aliño, M. (2015). Drogas legales emergentes: marihuana sintética, kratom, salvia divinorum, metoxetamina y los derivados de la piperazina. Revista Española de Drogodependencias, (1), 46–61.
  182. Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. The Lancet, 383(9930), 1749–1761.
  183. Ubeda-Bañon, I., Pro-Sistiaga, P., Mohedano-Moriano, A., Saiz-Sanchez, D., de la Rosa-Prieto, C., Gutierrez-Castellanos, N., … Martinez-Marcos, A. (2014). Cladistic analysis of olfactory and vomeronasal systems. Adaptive Function and Brain Evolution, 193.
  184. Vandrey, R. G., & Budney, A. J. (2015). Cannabis Use Disorders. Encyclopedia of Psychopharmacology, 336–341.
  185. Vasiliou, V., & Pappa, A. (2000). Polymorphisms of human aldehyde dehydrogenases. Pharmacology, 61(3), 192–198.
  186. Vasiliou, V., Pappa, A., & Estey, T. (2004). Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metabolism Reviews, 36(2), 279–299.
  187. Vitellone, N. (2015). Syringe sociology. The British Journal of Sociology, 66(2), 373–390.
  188. Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227.
  189. Watters, J. K., Estilo, M. J., Clark, G. L., & Lorvick, J. (1994). Syringe and needle exchange as HIV/AIDS prevention for injection drug users. Jama, 271(2), 115–120.
  190. Waxman, S. G. (2013). Clinical Neuroanatomy (27th ed.). McGraw-Hill Education.
  191. Wayne, R. (2009). Plant Cell Biology (1st ed.). San Diego: Elsevier.
  192. Weil, A., & Rosen, W. (1983). Chocolate to morphine. Houghton Mifflin Company.
  193. Wiesner, C., & Peñaranda, D. (2002). Encuesta mundial de tabaquismo en jóvenes reporte de Bogotá, Colombia. Revista Colombiana de Cancerología, 6(4), 5–14.
  194. Wikler, A. (2013). Opioid dependence: Mechanisms and treatment. Springer Science & Business Media.
  195. Wise, R. A. (1984). Neural mechanisms of the reinforcing action of cocaine. Cocaine: Pharmacology, Effects, and Treatment of Abuse. National Institute on Drug Abuse Research Monograph, 50, 15–33.
  196. Wise, R. A., & Koob, G. F. (2014). The development and maintenance of drug addiction. Neuropsychopharmacology, 39(2), 254–262.
  197. Yasui, Y., & Su, T.-P. (2016). Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine. Journal of Drug and Alcohol Research, 5.
  198. Yoshida, A., Rzhetsky, A., Hsu, L. C., & Chang, C. (1998). Human aldehyde dehydrogenase gene family. European Journal of Biochemistry, 251(3), 549–557.
  199. Young, S. J., Longstaffe, S., & Tenenbein, M. (1999). Inhalant abuse and the abuse of other drugs. The American Journal of Drug and Alcohol Abuse, 25(2), 371–375.
  200. Zhang, L. R., Morgenstern, H., Greenland, S., Chang, S., Lazarus, P., Teare, M. D., … Brhane, Y. (2015). Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. International Journal of Cancer, 136(4), 894–903.

Sistema nervioso // Principal // Siguiente

No hay comentarios:

Publicar un comentario

Los que nos ven